Testosterone Injection |
Delatestryl; Depo-Testosterone |
Clinical Trial: Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men with Androgen Deficiency
This study has been completed.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Men with low testosterone levels | Drug: Testosterone Enanthate | Phase II Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Effects of Testosterone Administration on Tissues of Men with A.D.A.M. (Androgen Deficiency of Aging Men)
Expected Total Enrollment: 44
Study start: April 2003; Study completion: November 2004
Last follow-up: November 2004; Data entry closure: November 2004
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:Inclusion Criteria
- Male aged 50-80 years of age, ambulatory, and in good general physical and mental health.
- Clinical diagnosis of hypogonadism defined as a serum testosterone level less than 300 ng/dl on a morning serum sample during the screening period.
- Answering yes to question 1 or 7 or to any three questions total on the Morley index at baseline.
- PSA <10 ng/ml
- Subject is able to give informed consent.
Exclusion Criteria
- Failure to meet the criteria for inclusion
- History of allergy to testosterone or any components of the delivery system.
- Significant abnormalities on pre-study clinical examination or laboratory measurements.
- Treatment with any investigational drug during the previous month.
- Drug or alcohol abuse or dependence.
- Concurrent use of testosterone and or any hormonal therapy, including health food supplements and herbal products, that could alter serum testosterone levels or affect the prostate (e.g. gonadotropic releasing hormone agonists, testosterone antagonists, anabolic steroids, DHEA, androstenedione, PC-SPES, chrysin and tribulus terrestris,). Use of alpha-reductase inhibitors or prostate phytotherapy within the past 3 months.
- Use of antidepressant medications, oral glucocorticoids, or opioids.
- PSA > 10 ng/ml and/or prostate biopsy positive for cancer at screening. Any patient in whom there is a suspicion of prostate cancer must undergo appropriate testing to rule out cancer prior to entry into the study.
- IPSS score 20.
- History of malignancy of any type (except basal cell carcinoma).
- Patients with uncontrolled diabetes.
- Patients with known or suspected bleeding disorder. Concurrent use of Coumadin and other anticoagulants at the time of biopsy or if discontinuation of such therapy prior to biopsy poses a risk to the patient.
- Inability of the patient to provide written informed consent for any reason, including legal incompetence, language or comprehension difficulty, and psychological, psychiatric or emotional factors.
- Inability of the patient to have transrectal ultrasonography with biopsy (for any reason).
- A history of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient.
Location Information
California
Urological Sciences Research Foundation, Culver City, California, 90232, United States
Leonard S Marks, M.D., Principal Investigator, Urological Sciences Research Foundation
More Information
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00161304
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Delatestryl (Drug Digest)
- Depo-Testosterone (Drug Digest)

Not Signed In -


